Written by students who passed Immediately available after payment Read online or as PDF Wrong document? Swap it for free 4.6 TrustPilot
logo-home
Document preview thumbnail
Preview 3 out of 23 pages
Exam (elaborations)

NR565 week 5

Document preview thumbnail
Preview 3 out of 23 pages

NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5NR565 week 5

Content preview

NR565 week 5
- Be able to calculate the total daily dose of insulin based on weight. Calculate with the lowest possible
dose unless otherwise specified. - ANSWER✅✅✅For example, the total daily dose (TDD) of insulin
can be calculated by taking the total weight of the patient's weight in kilograms (kg), which is 80 kg (184
pounds) multiplied by 0.6 units equals 48 units. This means 24 units of the TDD is the basal insulin dose
of glargine (Lantus) (50%) and the other 24 units of rapid-acting bolus/mealtime insulin (50%).



80x0.6= 48 (tdd)



- Be familiar with benefits of various nicotine replacement options - ANSWER✅✅✅Nicotine Chewing
Gum (Nicotine Polacrilex):

Nonprescription; user controls dose



Nicotine Lozenges (Nicotine Polacrilex):

Nonprescription; user controls dose; easier to use than nicotine gum



Nicotine Transdermal Systems (Patches):

Nonprescription; provides a steady level of nicotine; easy to use; unobtrusive



Nicotine inhaler:

User controls dose; mimics hand-to-mouth motion of smoking



Nicotine nasal spray:

User controls dose; fastest nicotine delivery and highest nicotine levels of all nicotine-based products



- Be familiar with frequency of Hgb A1C monitoring timeline. - ANSWER✅✅✅Perform the A1C test
at least two times a year in patients who are meeting treatment goals (and who have stable glycemic
control). E



Perform the A1C test quarterly in patients whose therapy has changed or who are not meeting glycemic
goals. E

,NR565 week 5
Point-of-care testing for A1C provides the opportunity for more timely treatment changes. E



pg. 398



- Be familiar with metoclopramide's use, MOA, side effects, monitoring and patient teaching. -
ANSWER✅✅✅Metoclopramide (Reglan) has two beneficial actions: (1) it suppresses emesis (by
blocking receptors for dopamine and serotonin in the CTZ), and (2) it increases upper GI motility (by
enhancing the actions of acetylcholine).



Indications depend on the route (oral or intravenous). Oral metoclopramide has two approved uses:
diabetic gastroparesis and suppression of gastroesophageal reflux. Intravenous metoclopramide has
four approved uses: suppression of postoperative nausea and vomiting, suppression of CINV, facilitation
of small bowel intubation, and facilitation of radiologic examination of the GI tract. Off-label uses
include the treatment of hiccups and nausea and vomiting of early pregnancy.



Adverse Effects

With high-dose therapy, sedation and diarrhea are common. Long-term high-dose therapy can cause
irreversible tardive dyskinesia, characterized by repetitive, involuntary movements of the arms, legs,
and facial muscles. Older adults are especially vulnerable and can develop involuntary movement
disorders after a single dose. To reduce the risk for tardive dyskinesia, treatment should be as brief as
possible using the lowest effective dose. Owing to its ability to increase gastric and intestinal motility,
metoclopramide is contraindicated in patients with GI obstruction, perforation, or hemorrhage. Of note,
exposure to metoclopramide during the first trimester of pregnancy is not associated with an excess risk
for congenital malformations.



- Be familiar with roflumilast - Know when to use LABA, SABA, Combo drugs in COPD -
ANSWER✅✅✅One phosphodiesterase 4 (PDE4) inhibitor, Roflumilast (Daliresp. Daxas) is approved
for management of COPD. In patients with severe, chronic COPD with a primary chronic bronchitis
component, the risk for exacerbations may be reduced with this drug.



Mechanism of action.

Roflumilast is a selective inhibitor of PDE, an enzyme that inactivates cyclic adenosine monophosphate
(cAMP). By raising levels of cAMP in lung cells, the drug reduces inflammation by suppressing cytokine
release and by decreasing pulmonary infiltration by neutrophils and other white blood cells. As a result,
cough and excessive mucus production are reduced and mucociliary clearance is improved.

, NR565 week 5

Therapeutic use.

Romflumilast is approved only for management of COPD. It is not a first-line drug; rather, it is used for
exacerbation prophylaxis in patients with severe COPD with a primary chronic bronchitis component and
a history of frequent exacerbations.



Pharmacokinetics.

Romflumilast has a bioavailability approximating 80%. It peaks in approximately 1 hour, although this is
delayed if taken with food. It is 99% protein bound with a half-life of 17 hours. Metabolism to its active
metabolite is via CYP3A4 and CYP1A2 isoenzymes. Excretions is primarily through urine.



Adverse effects.

Adverse effects include diarrhea, reduced appetite, weight loss, nausea, headache, back pain, and
insomnia. It should be prescribed with caution for patients with depression. Safety in pregnancy has not
been established; however, adverse events occurred in animal reproduction studies. Breastfeeding is
not recommended when taking this drug. That being said, because COPD is uncommonly among women
of child-bearing age, this is not typically a concern.



- Be familiar with routine recommended vaccination schedules- not catch-up schedules -
ANSWER✅✅✅



- Be familiar with the rabies vaccination schedule. - ANSWER✅✅✅4 1-mL doses of HDCV or PCECV
IM. First dose ASAP after exposure (day 0), followed by days 3, 7, 14. Along with RIG (rabies immune
globulin).



If patient immunocompromised, 5 injections on days 0, 3, 7, 14, and 28.



Previous vaccine, 2 doses on day 0 and day 3 with no RIG.



- Be familiar with treatment algorithm for DM and when to increase or decrease insulin. -
ANSWER✅✅✅Slide 1:

The first-line treatment for all patients with diabetes is Metformin and lifestyle changes. Comprehensive
lifestyle management is key to improving health.

Document information

Uploaded on
September 21, 2024
Number of pages
23
Written in
2024/2025
Type
Exam (elaborations)
Contains
Questions & answers
$23.99

Wrong document? Swap it for free Within 14 days of purchase and before downloading, you can choose a different document. You can simply spend the amount again.
Written by students who passed
Immediately available after payment
Read online or as PDF

Seller avatar
Reputation scores are based on the amount of documents a seller has sold for a fee and the reviews they have received for those documents. There are three levels: Bronze, Silver and Gold. The better the reputation, the more your can rely on the quality of the sellers work.
Creativepdf
3.8
(5)
Sold
38
Followers
28
Items
2597
Last sold
5 months ago


Why students choose Stuvia

Created by fellow students, verified by reviews

Quality you can trust: written by students who passed their tests and reviewed by others who've used these notes.

Didn't get what you expected? Choose another document

No worries! You can instantly pick a different document that better fits what you're looking for.

Pay as you like, start learning right away

No subscription, no commitments. Pay the way you're used to via credit card and download your PDF document instantly.

Student with book image

“Bought, downloaded, and aced it. It really can be that simple.”

Alisha Student

Working on your references?

Create accurate citations in APA, MLA and Harvard with our free citation generator.

Working on your references?

Frequently asked questions